DK3221298T3 - 4-oxo-3,4-dihydro-1,2,3-benzotriazinderivater som modulatorer af gpr139 - Google Patents

4-oxo-3,4-dihydro-1,2,3-benzotriazinderivater som modulatorer af gpr139 Download PDF

Info

Publication number: DK3221298T3
Authority: DK; Denmark
Prior art keywords: gpr139; modulators; dihydro; oxo; benzotriazine derivatives
Prior art date: 2014-11-20

Application number

DK15816275.0T

Other languages

English (en)

Inventor

Stephen Hitchcock

Betty Lam

Holger Monenschein

Holly Reichard

Original Assignee

Takeda Pharmaceuticals Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-11-20

Filing date

2015-11-19

Publication date

2019-06-24

2015-11-19 Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co

2019-06-24 Application granted granted Critical

2019-06-24 Publication of DK3221298T3 publication Critical patent/DK3221298T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Addiction (AREA)
Child & Adolescent Psychology (AREA)
Hospice & Palliative Care (AREA)
Anesthesiology (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

DK15816275.0T 2014-11-20 2015-11-19 4-oxo-3,4-dihydro-1,2,3-benzotriazinderivater som modulatorer af gpr139 DK3221298T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201462082539P	2014-11-20	2014-11-20
US201562184729P	2015-06-25	2015-06-25
PCT/US2015/061607 WO2016081736A1 (en)	2014-11-20	2015-11-19	4-oxo-3,4-dihydro-1,2,3-benzotriazines as modulators of gpr139

Publications (1)

Publication Number	Publication Date
DK3221298T3 true DK3221298T3 (da)	2019-06-24

Family

ID=55022667

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK15816275.0T DK3221298T3 (da)	2014-11-20	2015-11-19	4-oxo-3,4-dihydro-1,2,3-benzotriazinderivater som modulatorer af gpr139
DK19152036.0T DK3536324T3 (da)	2014-11-20	2015-11-19	4-oxo-3,4-dihydro-1,2,3-benzotriaziner som modulatorer af gpr139

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK19152036.0T DK3536324T3 (da)	2014-11-20	2015-11-19	4-oxo-3,4-dihydro-1,2,3-benzotriaziner som modulatorer af gpr139

Country Status (40)

Country	Link
US (5)	US9556130B2 (da)
EP (2)	EP3536324B1 (da)
JP (2)	JP6637501B2 (da)
KR (1)	KR102582021B1 (da)
CN (2)	CN107108531B (da)
AU (1)	AU2015349866B2 (da)
CA (1)	CA2968242C (da)
CL (1)	CL2017001292A1 (da)
CO (1)	CO2017005959A2 (da)
CR (1)	CR20170275A (da)
CY (2)	CY1122613T1 (da)
DK (2)	DK3221298T3 (da)
DO (1)	DOP2017000120A (da)
EA (1)	EA033728B1 (da)
EC (1)	ECSP17038999A (da)
ES (2)	ES2734735T3 (da)
GE (2)	GEP20196961B (da)
HR (2)	HRP20191003T1 (da)
HU (2)	HUE044145T2 (da)
IL (1)	IL252311B (da)
JO (1)	JO3719B1 (da)
LT (2)	LT3221298T (da)
MA (1)	MA40993B1 (da)
MD (1)	MD3221298T2 (da)
MX (1)	MX378158B (da)
MY (1)	MY187423A (da)
NZ (1)	NZ732208A (da)
PE (1)	PE20170899A1 (da)
PH (1)	PH12017500920B1 (da)
PL (2)	PL3536324T3 (da)
PT (2)	PT3221298T (da)
RS (2)	RS62563B1 (da)
SG (1)	SG11201704002UA (da)
SI (2)	SI3221298T1 (da)
SM (2)	SMT202200142T1 (da)
TN (1)	TN2017000196A1 (da)
TW (1)	TWI684590B (da)
UA (1)	UA120375C2 (da)
UY (1)	UY36406A (da)
WO (1)	WO2016081736A1 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JO3719B1 (ar) *	2014-11-20	2021-01-31	Takeda Pharmaceuticals Co	4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139
WO2020081538A1 (en)	2018-10-16	2020-04-23	The Scripps Research Institute	Methods related to opioid therapeutics
WO2020097609A1 (en)	2018-11-09	2020-05-14	Blackthorn Therapeutics, Inc.	Gpr139 receptor modulators
JOP20220063A1 (ar) *	2019-09-16	2023-01-30	Takeda Pharmaceuticals Co	مشتقات بيريدازين-3(2h)-أون ملتحمة بأزول
WO2021127459A1 (en) *	2019-12-20	2021-06-24	Blackthorn Therapeutics, Inc.	Gpr139 receptor modulators
JP7697974B2 (ja) *	2020-05-08	2025-06-24	武田薬品工業株式会社	Ｇｐｒ１３９アゴニストの置換ベンゾトリアジノン代謝物
JP2023541485A (ja) *	2020-09-21	2023-10-02	武田薬品工業株式会社	統合失調症のための処置
US11760788B2 (en)	2021-03-02	2023-09-19	Pathways Neuro Pharma, Inc.	Neuroreceptor compositions and methods of use
WO2023165262A1 (zh) *	2022-03-01	2023-09-07	上海科技大学	噻吩并含氮杂环类化合物、含其的药物组合物、其制备方法及其应用
WO2023165263A1 (zh) *	2022-03-01	2023-09-07	上海科技大学	吡咯并三嗪酮类化合物、含其的药物组合物、其制备方法及其应用
CN117986183A (zh) *	2022-10-28	2024-05-07	浙江友宁生物医药科技有限公司	一种gpr139受体激动剂、其制备方法及其应用
WO2024102802A1 (en) *	2022-11-11	2024-05-16	Takeda Pharmaceutical Company Limited	Zelatriazin for the treatment of depression
WO2025119351A1 (zh) *	2023-12-08	2025-06-12	深圳湾实验室	Gpr139激动剂
CN120424068A (zh) *	2024-02-02	2025-08-05	上海科技大学	稠杂环类化合物与其制备方法、药物组合物及应用
CN121159462A (zh) *	2025-11-19	2025-12-19	杭州市第七人民医院(杭州市心理危机研究与干预中心)	喹唑啉酮类化合物及其在制备神经系统疾病药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3794726A (en)	1972-08-21	1974-02-26	Uniroyal Inc	Inhibiting aggressive behavior with 1,2,3-benzotriazin-(3h)-one
DE3752141T2 (de)	1986-02-24	1998-03-26	Mitsui Petrochemical Ind	Mittel zur behandlung von neuropathie
EP0315390B1 (en) *	1987-11-04	1994-07-20	Beecham Group Plc	Novel 4-oxobenzotriazines and 4-oxoquinazolines
WO2004108673A2 (en)	2003-06-09	2004-12-16	Boehringer Ingelheim International Gmbh	Inhibitors of papilloma virus
CA2533824A1 (en)	2003-07-31	2005-02-10	Irm, Llc	Bicyclic compounds and compositions as pdf inhibitors
FR2875805B1 (fr)	2004-09-27	2006-12-29	Genfit S A	Composes derives de n-(benzyl) phenylacetamide substitues, preparation et utilisations
TW200736227A (en)	2005-12-23	2007-10-01	Astrazeneca Ab	New compounds III
TWI433839B (zh)	2006-08-11	2014-04-11	Neomed Inst	新穎的苯并咪唑衍生物290
CN101641358A (zh) *	2007-03-23	2010-02-03	霍夫曼-拉罗奇有限公司	氮杂-吡啶并嘧啶酮衍生物
WO2009086303A2 (en)	2007-12-21	2009-07-09	University Of Rochester	Method for altering the lifespan of eukaryotic organisms
WO2011138265A2 (en)	2010-05-03	2011-11-10	Evotec Ag	Indole and indazole derivatives as orexin receptor antagonists
US20140336216A1 (en)	2013-03-14	2014-11-13	Janssen Pharmaceutica Nv	Physiological ligands for gpr139
JO3719B1 (ar) *	2014-11-20	2021-01-31	Takeda Pharmaceuticals Co	4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139

2015
- 2015-11-18 JO JOP/2015/0282A patent/JO3719B1/ar active
- 2015-11-19 EA EA201791096A patent/EA033728B1/ru unknown
- 2015-11-19 UA UAA201705041A patent/UA120375C2/uk unknown
- 2015-11-19 SI SI201530772T patent/SI3221298T1/sl unknown
- 2015-11-19 TW TW104138295A patent/TWI684590B/zh active
- 2015-11-19 HU HUE15816275A patent/HUE044145T2/hu unknown
- 2015-11-19 DK DK15816275.0T patent/DK3221298T3/da active
- 2015-11-19 WO PCT/US2015/061607 patent/WO2016081736A1/en not_active Ceased
- 2015-11-19 GE GEAP201514515A patent/GEP20196961B/en unknown
- 2015-11-19 US US14/946,194 patent/US9556130B2/en active Active
- 2015-11-19 SM SM20220142T patent/SMT202200142T1/it unknown
- 2015-11-19 RS RS20211398A patent/RS62563B1/sr unknown
- 2015-11-19 GE GEAP201814515A patent/GEAP201814515A/en unknown
- 2015-11-19 LT LTEP15816275.0T patent/LT3221298T/lt unknown
- 2015-11-19 SM SM20190355T patent/SMT201900355T1/it unknown
- 2015-11-19 EP EP19152036.0A patent/EP3536324B1/en active Active
- 2015-11-19 PT PT15816275T patent/PT3221298T/pt unknown
- 2015-11-19 RS RS20190776A patent/RS59078B1/sr unknown
- 2015-11-19 CN CN201580071393.8A patent/CN107108531B/zh active Active
- 2015-11-19 ES ES15816275T patent/ES2734735T3/es active Active
- 2015-11-19 DK DK19152036.0T patent/DK3536324T3/da active
- 2015-11-19 JP JP2017526844A patent/JP6637501B2/ja active Active
- 2015-11-19 HR HRP20191003TT patent/HRP20191003T1/hr unknown
- 2015-11-19 AU AU2015349866A patent/AU2015349866B2/en active Active
- 2015-11-19 LT LTEP19152036.0T patent/LT3536324T/lt unknown
- 2015-11-19 ES ES19152036T patent/ES2897545T3/es active Active
- 2015-11-19 HR HRP20212009TT patent/HRP20212009T1/hr unknown
- 2015-11-19 PL PL19152036T patent/PL3536324T3/pl unknown
- 2015-11-19 PE PE2017000866A patent/PE20170899A1/es unknown
- 2015-11-19 CR CR20170275A patent/CR20170275A/es unknown
- 2015-11-19 CA CA2968242A patent/CA2968242C/en active Active
- 2015-11-19 HU HUE19152036A patent/HUE057451T2/hu unknown
- 2015-11-19 PL PL15816275T patent/PL3221298T3/pl unknown
- 2015-11-19 SG SG11201704002UA patent/SG11201704002UA/en unknown
- 2015-11-19 MY MYPI2017701778A patent/MY187423A/en unknown
- 2015-11-19 CN CN202010988947.3A patent/CN112062730B/zh active Active
- 2015-11-19 SI SI201531729T patent/SI3536324T1/sl unknown
- 2015-11-19 UY UY0001036406A patent/UY36406A/es not_active Application Discontinuation
- 2015-11-19 MX MX2017006448A patent/MX378158B/es unknown
- 2015-11-19 MD MDE20170117 patent/MD3221298T2/ro unknown
- 2015-11-19 TN TN2017000196A patent/TN2017000196A1/en unknown
- 2015-11-19 NZ NZ732208A patent/NZ732208A/en unknown
- 2015-11-19 EP EP15816275.0A patent/EP3221298B1/en active Active
- 2015-11-19 KR KR1020177016973A patent/KR102582021B1/ko active Active
- 2015-11-19 PT PT191520360T patent/PT3536324T/pt unknown
- 2015-11-19 MA MA40993A patent/MA40993B1/fr unknown
2016
- 2016-12-16 US US15/382,490 patent/US9770450B2/en active Active
2017
- 2017-05-12 DO DO2017000120A patent/DOP2017000120A/es unknown
- 2017-05-16 IL IL252311A patent/IL252311B/en active IP Right Grant
- 2017-05-18 PH PH12017500920A patent/PH12017500920B1/en unknown
- 2017-05-19 CL CL2017001292A patent/CL2017001292A1/es unknown
- 2017-06-16 CO CONC2017/0005959A patent/CO2017005959A2/es unknown
- 2017-06-20 EC ECIEPI201738999A patent/ECSP17038999A/es unknown
- 2017-08-22 US US15/683,589 patent/US10159677B2/en active Active
2018
- 2018-11-02 US US16/179,709 patent/US10561662B2/en active Active
2019
- 2019-06-20 CY CY20191100646T patent/CY1122613T1/el unknown
- 2019-12-20 JP JP2019229837A patent/JP6918088B2/ja active Active
2020
- 2020-01-02 US US16/732,536 patent/US11173161B2/en active Active
2021
- 2021-12-17 CY CY20211101111T patent/CY1124929T1/el unknown

Also Published As

Publication number	Publication date
EP3536324B1 (en)	2021-10-06
CN107108531B (zh)	2020-10-20
PL3536324T3 (pl)	2022-02-07
DK3536324T3 (da)	2021-10-25
KR102582021B1 (ko)	2023-09-22
PL3221298T3 (pl)	2019-10-31
SMT202200142T1 (it)	2022-05-12
NZ732208A (en)	2023-02-24
EP3221298B1 (en)	2019-04-03
US9556130B2 (en)	2017-01-31
US20170348319A1 (en)	2017-12-07
ES2897545T3 (es)	2022-03-01
JP6918088B2 (ja)	2021-08-11
CY1122613T1 (el)	2021-05-05
SI3536324T1 (sl)	2021-12-31
UY36406A (es)	2016-06-30
MD3221298T2 (ro)	2019-10-31
CN112062730B (zh)	2023-09-29
JP2020063285A (ja)	2020-04-23
EA033728B1 (ru)	2019-11-20
CN112062730A (zh)	2020-12-11
HRP20212009T1 (hr)	2022-04-01
CY1124929T1 (el)	2023-01-05
US9770450B2 (en)	2017-09-26
BR112017010311A2 (pt)	2017-12-26
US20170095480A1 (en)	2017-04-06
RS62563B1 (sr)	2021-12-31
MX2017006448A (es)	2017-09-12
RS59078B1 (sr)	2019-09-30
ES2734735T3 (es)	2019-12-11
GEAP201814515A (en)	2018-12-10
SI3221298T1 (sl)	2019-10-30
CA2968242A1 (en)	2016-05-26
CR20170275A (es)	2017-10-30
MY187423A (en)	2021-09-22
PT3221298T (pt)	2019-06-28
GEP20196961B (en)	2019-03-25
HUE057451T2 (hu)	2022-05-28
PE20170899A1 (es)	2017-07-12
ECSP17038999A (es)	2017-10-31
IL252311B (en)	2020-07-30
MX378158B (es)	2025-03-10
DOP2017000120A (es)	2017-06-15
AU2015349866B2 (en)	2020-12-03
EP3536324A1 (en)	2019-09-11
JO3719B1 (ar)	2021-01-31
IL252311A0 (en)	2017-07-31
US20190070187A1 (en)	2019-03-07
SG11201704002UA (en)	2017-06-29
TN2017000196A1 (en)	2018-10-19
PH12017500920A1 (en)	2017-11-20
EP3221298A1 (en)	2017-09-27
EA201791096A1 (ru)	2017-11-30
US11173161B2 (en)	2021-11-16
CO2017005959A2 (es)	2017-10-20
KR20170084324A (ko)	2017-07-19
US10159677B2 (en)	2018-12-25
PH12017500920B1 (en)	2017-11-20
AU2015349866A1 (en)	2017-06-15
HRP20191003T1 (hr)	2019-08-23
HUE044145T2 (hu)	2019-09-30
JP2017535559A (ja)	2017-11-30
CL2017001292A1 (es)	2018-02-16
TWI684590B (zh)	2020-02-11
MA40993B1 (fr)	2019-07-31
US20160145218A1 (en)	2016-05-26
JP6637501B2 (ja)	2020-01-29
TW201625566A (zh)	2016-07-16
SMT201900355T1 (it)	2019-07-11
LT3221298T (lt)	2019-08-12
UA120375C2 (uk)	2019-11-25
PT3536324T (pt)	2021-11-10
LT3536324T (lt)	2021-12-10
CA2968242C (en)	2022-11-08
US20200129518A1 (en)	2020-04-30
MA40993A (fr)	2017-09-27
WO2016081736A1 (en)	2016-05-26
CN107108531A (zh)	2017-08-29
US10561662B2 (en)	2020-02-18

Publication	Publication Date	Title
DK3221298T3 (da)	2019-06-24	4-oxo-3,4-dihydro-1,2,3-benzotriazinderivater som modulatorer af gpr139
DK3521282T3 (da)	2021-09-27	Quinazolinderivater anvendt til behandling af hiv
DK3636649T3 (da)	2024-05-21	Diarylmakrocykler som modulatorer af proteinkinaser
DK3357919T3 (da)	2020-02-17	Aromatiske heterocykliske forbindelser som antiinflammatoriske forbindelser
BR112016030368A2 (pt)	2018-07-17	composição oftálmica
DK3137169T3 (da)	2022-02-14	Hæmmere af lysin-specifik demethylase-1
DK3178817T3 (da)	2020-07-13	Amorf form af tetracyklisk forbindelse
DK3094631T4 (da)	2025-03-03	Pyrimidinyloxybenzenderivater som herbicider
DK3204378T6 (da)	2022-07-18	N-pyridinylacetamidderivater som hæmmere af wnt-signaleringsbanen
LT3204359T (lt)	2020-10-12	Tetrahidroizochinolino dariniai
HUE048321T2 (hu)	2020-07-28	Karabazol származékok
DK3134410T3 (da)	2021-04-26	Hæmning af ionkanalen af overgangsreceptorpotentialet A1
DK3231803T3 (da)	2020-08-24	Dihydroindolizinonderivat
DK3164123T3 (da)	2020-08-03	Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier
DK3418273T3 (da)	2022-03-21	Derivater af flavagliner
DK3212643T3 (da)	2019-05-13	Trifluormethylalkoholer som modulatorer af ror-gamma-t
PT3131898T (pt)	2020-06-17	Derivados de fluoroalquilfluoreno
EP3554637A4 (en)	2020-05-20	Spiropiperidine derivatives
DK3145916T3 (da)	2020-05-11	Imidazolderivater som formylpeptidreceptormodulatorer
FR3021414B1 (fr)	2022-09-09	Miroir colore
PL3137460T3 (pl)	2020-04-30	Pochodne diheterocyklu połączonego cykloalkilem
LT3097076T (lt)	2019-08-26	Nauji cip-eikozanoidų dariniai
DK3148976T3 (da)	2019-05-27	Fremgangsmåde til fremstilling af dihydroisoxazolderivater
IL252908A0 (en)	2017-08-31	Fumagillol derivatives
DK3154942T3 (da)	2019-11-18	Fremstilling af piperidin-4-carbothioamid